Patents by Inventor Martina Delbeck

Martina Delbeck has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250154175
    Abstract: The present invention relates to novel diazabicyclically substituted imidazo[1,2-a]pyrimidine derivatives, to methods for producing the same, to the use thereof either alone or in combinations for the treatment and/or prevention of diseases, as well as to their use for preparing medicaments for the treatment and/or prevention of diseases, especially for treatment and/or prevention of breathing disorders, including sleep-related breathing disorders such as obstructive and central sleep apnoea and snoring.
    Type: Application
    Filed: November 21, 2024
    Publication date: May 15, 2025
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Martina DELBECK, Michael Hahn, Thomas Müller, Klemens Lustig, Karl Collins, Niels Lindner, Janine Nicolai, Moritz Beck-Broichsitter, Udo Albus, Doris Gehring, BjÖrn Rosenstein
  • Publication number: 20250074899
    Abstract: The present invention relates to ?2-Adrenoceptor subtype C (alpha-2C) antagonists, in particular 3-substituted 1-(2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl)azacycles of formula (I) for the use in a method for the treatment and/or prophylaxis of sleep-related breathing disorders, preferably obstructive and central sleep apneas and snoring.
    Type: Application
    Filed: January 5, 2023
    Publication date: March 6, 2025
    Inventors: Martina DELBECK, Michael HAHN
  • Publication number: 20250057846
    Abstract: The present invention relates to a combination of selective blockers of TASK-1 and TASK-3 channels, in particular substituted imidazo[1,2-a]pyrimidine and substituted imidazo[1,2-a]pyridine derivatives of formula (I) and muscarinic receptor antagonists for the treatment and/or prophylaxis of sleep-related breathing disorders, preferably obstructive and central sleep apneas and snoring.
    Type: Application
    Filed: December 20, 2022
    Publication date: February 20, 2025
    Inventors: Martina DELBECK, Michael HAHN
  • Publication number: 20250057845
    Abstract: The present invention relates to a combination of selective blockers of TASK-1 and TASK-3 channels, in particular substituted imidazo[1,2-a]pyrimidine and substituted imidazo[1,2-a]pyridine derivatives of formula (I) and P2X3 receptor antagonists for the treatment and/or prophylaxis of sleep-related breathing disorders, preferably obstructive and central sleep apneas and snoring.
    Type: Application
    Filed: December 20, 2020
    Publication date: February 20, 2025
    Inventors: Martina DELBECK, Michael HAHN
  • Publication number: 20250057828
    Abstract: The present invention relates to a combination of a muscarinic receptor antagonist and ?2-Adrenoceptor subtype C (alpha-2C) antagonists, in particular substituted heterocyclic carboxamides of formula (I) for the treatment and/or prophylaxis of sleep-related breathing disorders, preferably obstructive and central sleep apneas and snoring.
    Type: Application
    Filed: December 20, 2022
    Publication date: February 20, 2025
    Inventors: Martina DELBECK, Michael HAHN
  • Publication number: 20250049788
    Abstract: The present invention relates to ?2-Adrenoceptor subtype C (alpha-2C) antagonists, in particular 2,3-Dihydrobenzo[b][1,4]dioxin-2-ylmethyl)piperazin-1-yl derivates of formula (I) for the use in a method for the treatment and/or prophylaxis of sleep-related breathing disorders, preferably obstructive and central sleep apneas and snoring.
    Type: Application
    Filed: January 5, 2023
    Publication date: February 13, 2025
    Inventors: Martina DELBECK, Michael HAHN
  • Publication number: 20250049803
    Abstract: The present invention relates to a combination of selective blockers of TASK-1 and TASK-3 channels, in particular substituted imidazo[1,2-a]pyrimidine and substituted imidazo[1,2-a]pyridine derivatives of formula (I) and norepinephrine reuptake inhibitors for the treatment and/or prophylaxis of sleep-related breathing disorders, preferably obstructive and central sleep apneas and snoring.
    Type: Application
    Filed: December 20, 2022
    Publication date: February 13, 2025
    Inventors: Martina DELBECK, Michael HAHN
  • Publication number: 20250049779
    Abstract: The present invention relates to a combination of a noradrenaline reuptake inhibitor and ?2-Adrenoceptor subtype C (alpha-2C) antagonists, in particular substituted heterocyclic carboxamides of formula (I) for the treatment and/or prophylaxis of sleep-related breathing disorders, preferably obstructive and central sleep apneas and snoring.
    Type: Application
    Filed: December 20, 2022
    Publication date: February 13, 2025
    Inventors: Dr. Martina DELBECK, Dr. Michael HAHN
  • Patent number: 12180227
    Abstract: The present invention relates to novel diazabicyclically substituted imidazo[1,2-a]pyrimidine derivatives, such as compounds of the general formula (I): to methods for producing the same, to the use thereof either alone or in combinations for the treatment and/or prevention of diseases, as well as to their use for preparing medicaments for the treatment and/or prevention of diseases, especially for treatment and/or prevention of breathing disorders, including sleep-related breathing disorders such as obstructive and central sleep apnoea and snoring.
    Type: Grant
    Filed: July 16, 2021
    Date of Patent: December 31, 2024
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Martina Delbeck, Michael Hahn, Thomas Müller, Klemens Lustig, Karl Collins, Niels Lindner, Janine Nicolai, Moritz Beck-Broichsitter, Udo Albus, Doris Gehring, Björn Rosenstein
  • Publication number: 20240000767
    Abstract: The present invention relates to a combination of selective blockers of TASK-1 and TASK-3 channels, in particular substituted imidazo [1,2-a]pyrimidine and substituted imidazo [1,2-a]pyridine derivatives of formula (II) and ?2-Adrenoceptor subtype C (alpha-2C) antagonists, in particular substituted heterocyclic carboxamides of formula (I) for the treatment and/or prophylaxis of sleep-related breathing disorders, preferably obstructive and central sleep apneas and snoring.
    Type: Application
    Filed: July 5, 2021
    Publication date: January 4, 2024
    Applicant: Bayer Aktiengesellschaft
    Inventors: Martina DELBECK, Michael HAHN
  • Publication number: 20230115270
    Abstract: The present application relates to novel substituted heterocyclic carboxamides, to processes for their preparation, to their use alone or in combinations for the treatment and/or prevention of diseases and to their use for producing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of breathing difficulties including sleep-induced breathing difficulties such as central and obstructive sleep apnoea, snoring (primary and obstructive snoring), dysphagia, peripheral and cardiac vascular disorders including diabetic microangiopathies and disorders of the peripheral and central nervous system including neurodegenerative and neuroinflammatory disorders.
    Type: Application
    Filed: November 5, 2020
    Publication date: April 13, 2023
    Applicants: Bayer Aktiengesellschaft, Bayer Aktiengesellschaft
    Inventors: Martina DELBECK, Michael HAHN, Thomas MÜLLER, Lisa DIETZ, Magdalena PLATZK, Daniel MEIBOM, Philipp BUCHGRABER, Niels LINDNER, Eva Maria BECKER-PELSTER, Carsten SCHMECK
  • Publication number: 20220259228
    Abstract: The present application relates to novel (imidazo[1,2-a]pyridin-3-yl)methyl-substituted diazaheterobicyclic compounds, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of respiratory disorders including sleep-related respiratory disorders such as obstructive sleep apnoea and central sleep apnoea and snoring. The present application further relates to a method of discovering a compound having TASK-1- and/or TASK-3-blocking properties.
    Type: Application
    Filed: September 15, 2021
    Publication date: August 18, 2022
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Martina DELBECK, Michael Hahn, Thomas Müller, Klemens Lustig, Johanna Anlahr, Udo Albus, Doris Gehring, Björn Rosenstein, Karl Collins, Niels Lindner, Janine Nicolai, Moritz Beck-Broichsitter
  • Publication number: 20220218677
    Abstract: The present invention relates to ?2-Adrenoceptor subtype C (alpha-2C) antagonists, in particular arylquinolizine derivatives of formula (I) for the use in a method for the treatment and/or prophylaxis of sleep-related breathing disorders, preferably obstructive and central sleep apneas and snoring.
    Type: Application
    Filed: May 4, 2020
    Publication date: July 14, 2022
    Applicant: Bayer Aktiengesellschaft
    Inventors: Martina DELBECK, Michael HAHN
  • Publication number: 20220218695
    Abstract: The present invention relates to a combination of selective blockers of TASK-1 and TASK-3 channels, in particular diazabicyclically substituted imidazo [1,2-a]pyrimidine derivatives and ?2-Adrenoceptor subtype C (alpha-2C) antagonists, in particular arylquinolizine derivatives of formula (I) for the treatment and/or prophylaxis of sleep-related breathing disorders, preferably obstructive and central sleep apneas and snoring.
    Type: Application
    Filed: May 4, 2020
    Publication date: July 14, 2022
    Applicant: Bayer Aktiengesellschaft
    Inventors: Martina DELBECK, Michael HAHN
  • Publication number: 20220218700
    Abstract: The present invention relates to a combination of selective blockers of TASK-1 and TASK-3 channels, in particular diazabicyclically substituted imidazo[1,2-a]pyrimidine derivatives and ?2-Adrenoceptor subtype C (alpha-2C) antagonists, in particular aryl piperazines of formula (I) for the treatment and/or prophylaxis of sleep-related breathing disorders, preferably obstructive and central sleep apneas and snoring.
    Type: Application
    Filed: May 4, 2020
    Publication date: July 14, 2022
    Applicant: Bayer Aktiengesellschaft
    Inventors: Martina DELBECK, Michael HAHN
  • Publication number: 20220016113
    Abstract: (alpha-2C) antagonists, in particular substituted piperidinyl-pyrimidinyl-tetra hydrochinolines and piperidinyl-pyridinyl-tetrahydrochinolines of formula (I) for the use in a method for the treatment and/or prophylaxis of sleep-related breathing disorders, preferably obstructive and central sleep apneas and snoring. Formula (I) in which X is a group (A) or (B).
    Type: Application
    Filed: November 13, 2019
    Publication date: January 20, 2022
    Applicant: Bayer Aktiengesellschaft
    Inventors: Martina DELBECK, Michael HAHN
  • Publication number: 20220017540
    Abstract: The present invention relates to novel diazabicyclically substituted imidazo[1,2-a]pyrimidine derivatives, to methods for producing the same, to the use thereof either alone or in combinations for the treatment and/or prevention of diseases, as well as to their use for preparing medicaments for the treatment and/or prevention of diseases, especially for treatment and/or prevention of breathing disorders, including sleep-related breathing disorders such as obstructive and central sleep apnoea and snoring.
    Type: Application
    Filed: July 16, 2021
    Publication date: January 20, 2022
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Martina DELBECK, Michael HAHN, Thomas MÜLLER, Klemens LUSTIG, Karl COLLINS, Niels LINDNER, Janine NICOLAI, Moritz BECK-BROICHSITTER, Udo ALBUS, Doris GEHRING, Björn ROSENSTEIN
  • Patent number: 11208422
    Abstract: The present application relates to novel imidazopyridinyl- or imidazopyrimidinyl-substituted, bridged 1,4-diazepane derivatives of formula (I), to processes for their preparation, to their use alone or in combinations for the treatment and/or prevention of diseases, and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for treatment and/or prevention of respiratory disorders including, sleep-related respiratory disorders such as obstructive sleep apnoeas and central sleep apnoeas and snoring. Formula (I) in which the ring Q represents a bridged 1,4-diazepane cycle.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: December 28, 2021
    Assignees: Bayer Pharma Aktiengesellschaft, Bayer Aktiengesellschaft
    Inventors: Martina Delbeck, Michael Hahn, Thomas Müller, Klemens Lustig, Johanna Anlahr, Karl Collins, Janine Nicolai, Moritz Beck-Broichsitter, Udo Albus, Doris Gehring, Björn Rosenstein, Hongkai Dang, Dehe Duan, Jianfei Yang, Denghui Chen
  • Publication number: 20210338662
    Abstract: The present invention relates to ?2-Adrenoceptor subtype C (alpha-2C) antagonists, in particular aryl piperazines of formula (I) for the use in a method for the treatment and/or prophylaxis of sleep-related breathing disorders, preferably obstructive and central sleep apneas and snoring.
    Type: Application
    Filed: September 19, 2019
    Publication date: November 4, 2021
    Applicant: Bayer Aktiengeselischaft
    Inventors: Martina DELBECK, Michael HAHN
  • Patent number: 11098063
    Abstract: The present invention relates to novel diazabicyclically substituted imidazo[1,2-a]pyrimidine derivatives, to methods for producing the same, to the use thereof either alone or in combinations for the treatment and/or prevention of diseases, as well as to their use for preparing medicaments for the treatment and/or prevention of diseases, especially for treatment and/or prevention of breathing disorders, including sleep-related breathing disorders such as obstructive and central sleep apnoea and snoring.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: August 24, 2021
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Martina Delbeck, Michael Hahn, Thomas Müller, Klemens Lustig, Karl Collins, Niels Lindner, Janine Nicolai, Moritz Beck-Broichsitter, Udo Albus, Doris Gehring, Björn Rosenstein